Related references
Note: Only part of the references are listed.Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Lei Chen et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Transforming growth factor beta induces fibroblasts to express and release the immunomodulatory protein PD-L1 into extracellular vesicles
Jeong-Han Kang et al.
FASEB JOURNAL (2020)
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort
Neil H. Segal et al.
EUROPEAN JOURNAL OF CANCER (2019)
Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma
Julius Moratin et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2019)
Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
Jacob H. Rasmussen et al.
BRITISH JOURNAL OF CANCER (2019)
Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer
Angela M. Hong et al.
ORAL ONCOLOGY (2019)
TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2
Paramita Baruah et al.
FRONTIERS IN IMMUNOLOGY (2019)
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial
Barbara Burtness et al.
JAMA ONCOLOGY (2019)
Interferon β and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells
Anna Makowska et al.
TRANSLATIONAL ONCOLOGY (2019)
Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma
Lei Wu et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization
Nai-Yun Sun et al.
CANCERS (2019)
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma
Seong-Ho Kang et al.
ONCOIMMUNOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer A Phase 2 Clinical Trial
Erminia Massarelli et al.
JAMA ONCOLOGY (2019)
HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
Jian Wang et al.
SCIENTIFIC REPORTS (2019)
Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
M. Oliva et al.
ANNALS OF ONCOLOGY (2019)
Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients
Qinchuan Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
Paul Buderath et al.
FRONTIERS IN ONCOLOGY (2019)
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P. Zandberg et al.
EUROPEAN JOURNAL OF CANCER (2019)
Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients
Carolina Cubillos-Zapata et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
CheckMate 141 trial: all that glitters is not gold
Raffaele Addeo et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Histoepigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironments
Ivenise Carrero et al.
ONCOGENE (2019)
Immunotherapy for head and neck cancer: Recent advances and future directions
John D. Cramer et al.
ORAL ONCOLOGY (2019)
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection
Xintong Lyu et al.
JOURNAL OF CANCER (2019)
Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians
Sophie Outh-Gauer et al.
CANCER TREATMENT REVIEWS (2018)
Separation of plasma-derived exosomes into CD3(+) and CD3(-) fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients
M-N Theodoraki et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2018)
Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients
Zhuqing Liu et al.
CLINICAL CANCER RESEARCH (2018)
Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine
Yee Sun Tan et al.
CLINICAL CANCER RESEARCH (2018)
Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma
Jonathan D. Schoenfeld et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris et al.
ORAL ONCOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
Benjamin Solomon et al.
SEMINARS IN CANCER BIOLOGY (2018)
Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions
Rothschild Uta et al.
SWISS MEDICAL WEEKLY (2018)
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
Genevieve P. Hartley et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial
A. D. Colevas et al.
ANNALS OF ONCOLOGY (2018)
Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence
M. -N. Theodoraki et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2018)
The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis
Wei-fa Yang et al.
ORAL ONCOLOGY (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
PD-L1 Mediates Dysfunction in Activated PD-1(+) NK Cells in Head and Neck Cancer Patients
Fernando Concha-Benavente et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Frameshift events predict anti-PD-1/L1 response in head and neck cancer
Glenn J. Hanna et al.
JCI INSIGHT (2018)
Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer
Marij J. P. Welters et al.
CLINICAL CANCER RESEARCH (2018)
Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Marie-Nicole Theodoraki et al.
CLINICAL CANCER RESEARCH (2018)
Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment
Mariko Hirai et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
Gulidanna Shayan et al.
ONCOIMMUNOLOGY (2017)
Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-Ll expression on tumor-associated macrophages
Canhua Jiang et al.
IMMUNOBIOLOGY (2017)
The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
Panagiotis Balermpas et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comprehensive T-cell immunophenotyping and next-generation sequencing of human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinomas
Kate Poropatich et al.
JOURNAL OF PATHOLOGY (2017)
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Riccardo Mezzadra et al.
NATURE (2017)
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr et al.
NATURE (2017)
Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
Axel Lechner et al.
ONCOTARGET (2017)
Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients
Hyun-Bae Jie et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
Linda Tran et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy
Dan Ou et al.
ONCOIMMUNOLOGY (2017)
Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment
Corinne A. Levingston et al.
CANCERS (2017)
CD163+ CD204+ tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma
Keigo Kubota et al.
SCIENTIFIC REPORTS (2017)
PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer
Benjamin A. Kansy et al.
CANCER RESEARCH (2017)
PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs
Austin K. Mattox et al.
CANCER RESEARCH (2017)
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer
Fumi Sato-Kaneko et al.
JCI INSIGHT (2017)
Exosomes as new players in metabolic organ cross-talk
Claudiane Guay et al.
DIABETES OBESITY & METABOLISM (2017)
Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer
Sonja Ludwig et al.
CLINICAL CANCER RESEARCH (2017)
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
E. Saada-Bouzid et al.
ANNALS OF ONCOLOGY (2017)
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Jennifer H. Yearley et al.
CLINICAL CANCER RESEARCH (2017)
Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
Maria Vassilakopoulou et al.
CLINICAL CANCER RESEARCH (2016)
Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research
Kurt A. Schalper et al.
CLINICAL CANCER RESEARCH (2016)
CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1
Yunqin Lee et al.
CLINICAL CANCER RESEARCH (2016)
Exosomes and tumor-mediated immune suppression
Theresa L. Whiteside
JOURNAL OF CLINICAL INVESTIGATION (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials
Angela M. Hong et al.
ONCOTARGET (2016)
Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
Hae Su Kim et al.
CANCER RESEARCH AND TREATMENT (2016)
Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk
Jing Li et al.
ONCOIMMUNOLOGY (2016)
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
Hye Ryun Kim et al.
SCIENTIFIC REPORTS (2016)
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer
Ryan Montler et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2016)
Oral cavity and oropharyngeal squamous cell carcinomaan update
Angela C. Chi et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression
A. E. Rice et al.
CANCER GENE THERAPY (2015)
Immunology and Immunotherapy of Head and Neck Cancer
Robert L. Ferris
JOURNAL OF CLINICAL ONCOLOGY (2015)
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
Patcharee Ritprajak et al.
ORAL ONCOLOGY (2015)
PD-L1 Blockade for Cancer Treatment: MEDI4736
Ramy Ibrahim et al.
SEMINARS IN ONCOLOGY (2015)
PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPa axis in HPV negative head and neck squamous cell carcinoma
Guang-Tao Yu et al.
ONCOTARGET (2015)
Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma
Simona Partlova et al.
ONCOIMMUNOLOGY (2015)
Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma
Ian-James Malm et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2015)
High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma
Yueh-Min Lin et al.
PLOS ONE (2015)
Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
Chunxiao Xu et al.
CANCER CELL (2014)
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
H-B Jie et al.
BRITISH JOURNAL OF CANCER (2013)
PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
Cecile Badoual et al.
CANCER RESEARCH (2013)
Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
Sofia Lyford-Pike et al.
CANCER RESEARCH (2013)
The Immune Signature of CD8+CCR7+ T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC
Malgorzata Czystowska et al.
CLINICAL CANCER RESEARCH (2013)
Promising New Molecular Targeted Therapies in Head and Neck Cancer
Kelly Dorsey et al.
DRUGS (2013)
Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway
Jiao Chen et al.
IMMUNOBIOLOGY (2012)
PD-L2 is expressed on activated human T cells and regulates their function
Nassima Messal et al.
MOLECULAR IMMUNOLOGY (2011)
Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma
Young-Ah Cho et al.
ORAL ONCOLOGY (2011)
The molecular biology of head and neck cancer
C. Rene Leemans et al.
NATURE REVIEWS CANCER (2011)
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
Jang-June Park et al.
BLOOD (2010)
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Alberto Mantovani et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma
Mei-Chi Hsu et al.
MODERN PATHOLOGY (2010)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
Shawn D. Blackburn et al.
NATURE IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Recent advances in head and neck cancer
Robert I. Haddad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associllited T cells
Michael R. Nazareth et al.
JOURNAL OF IMMUNOLOGY (2007)
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma
M. E. Prince et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma
F Tsushima et al.
ORAL ONCOLOGY (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
LP Chen
NATURE REVIEWS IMMUNOLOGY (2004)
Endothelial expression of PD-L1 and PD-L2 down-regulates CD8(+) T cell activation and cytolysis
N Rodig et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Share Paper
